What is KPV?
KPV is a tripeptide (Lysine-Proline-Valine) derived from the C-terminal end of alpha-Melanocyte Stimulating Hormone (alpha-MSH). It represents the biologically active core sequence responsible for alpha-MSH's potent anti-inflammatory effects. KPV has been extensively studied for its role in modulating intestinal inflammation, wound healing, and immune response — particularly in the context of inflammatory bowel disease (IBD) and colitis.
Research Benefits
- Potent anti-inflammatory activity via MC1R receptor activation and NF-kB suppression
- Reduces intestinal inflammation and studied for colitis and IBD applications
- Promotes wound healing through keratinocyte stimulation and tissue remodeling
- Modulates skin inflammatory conditions including psoriasis and eczema in research models
- Crosses the blood-brain barrier — researched for neuroinflammation reduction
- Synergistic with BPC-157 for comprehensive gut health and inflammatory recovery protocols
Dosage & Protocol
Research protocols typically use 500 mcg–1 mg per day via subcutaneous injection. For gut-specific applications, oral administration is also studied. The short half-life of approximately 2 hours means twice-daily dosing may be optimal for sustained plasma levels. Standard research cycles are 4–8 weeks.
Frequently Asked Questions
KPV is primarily researched for its anti-inflammatory and gut-healing properties. It has the strongest evidence base for intestinal inflammation, IBD, and colitis research, where it reduces inflammatory cytokines and promotes mucosal healing.
Yes. KPV has been researched via oral administration for gut-specific applications. Studies show it maintains bioactivity in the GI tract, making it suitable for intestinal inflammation research without requiring injection.
KPV works primarily through anti-inflammatory MC1R and NF-kB pathways, while BPC-157 promotes gut lining repair via VEGFR2 and growth factor signaling. They address complementary mechanisms and are often used together in comprehensive gut recovery stacks.